# Fever of Unknown Origin

Evaluate persistent unexplained fever by separating classic FUO from neutropenic, nosocomial, and HIV-associated syndromes; repeatedly pursue localizing clues, obtain targeted microbiology and imaging, use FDG-PET/CT after unrevealing standard evaluation, and biopsy metabolically active or clinically abnormal tissue before empiric therapy.

**Clinical question:** How should physicians evaluate and manage an adult with persistent fever after an unrevealing initial diagnostic evaluation?

Updated: 2026-09-16T01:15:26.627357+00:00

## What matters in practice
- Reserve the label classic FUO for fever at least 38.3°C on at least two occasions, illness lasting at least 3 weeks, no known immunocompromised state, and no diagnosis after a defined baseline evaluation. [12]
- Use repeated history and examination to identify potential diagnostic clues; direct subsequent tests and tissue sampling toward these clues rather than ordering indiscriminate panels. [10][24]
- After standard evaluation is unrevealing, FDG-PET/CT can localize inflammatory, infectious, or neoplastic targets and can guide a higher-yield biopsy. [11][24]
- Avoid empiric antibacterial, antituberculous, or glucocorticoid treatment in clinically stable classic FUO when possible because treatment can obscure the diagnosis; febrile neutropenia is a separate emergency pathway. [5][13]

## Classify the febrile syndrome before using a classic FUO pathway

The host setting determines urgency, differential diagnosis, and whether empiric treatment is appropriate.

Apply the classic FUO framework only when fever is at least 38.3°C (101°F) on at least two occasions, illness has persisted at least 3 weeks, the patient has no known immunocompromised state, and diagnosis remains uncertain after thorough history, examination, and baseline testing. [12] Do not apply this slower diagnostic pathway to neutropenic fever, hospital-acquired fever, or fever in a person with HIV; these categories have distinct pathogen risks and management priorities. [5][13][21]

Screen immediately for neutropenic fever: a single oral temperature of at least 38.3°C or temperature of at least 38.0°C for at least 1 hour with absolute neutrophil count below 1,500 cells/µL meets the cited definition, while severe neutropenia is ANC below 500 cells/µL. [13] In a high-risk neutropenic patient, initiate broad-spectrum antibacterial management rather than prolonging an FUO evaluation; persistent fever after 4 to 7 days of broad-spectrum antibacterials with suspicion for fungal infection is an indication for empiric antifungal coverage. [13]

For apparent classic FUO, first verify the temperature record and review all prescription, over-the-counter, and recently discontinued medications for drug fever; also consider surreptitious thermometer manipulation when the evaluation remains unrevealing. [10] Reclassify any patient with a newly recognized immunocompromising condition, evolving organ dysfunction, or a focal syndrome, because that finding should redirect evaluation to the relevant acute syndrome rather than preserve an FUO label. [5][10]
- Use a neutropenic-fever pathway when fever occurs with ANC below 1,500 cells/µL; treat ANC below 500 cells/µL as severe neutropenia. [13]
- Use a nosocomial framework when hospitalization-related exposures, procedures, devices, or complications plausibly explain fever. [5]
- In people living with HIV who are hospitalized with FUO, prioritize bacterial infection while evaluating immune status and organ-specific clues. [21]

*Clinical setting changes the initial pathway. [5][12][13][21]*

| Syndrome | Operational discriminator | Immediate next step |
| --- | --- | --- |
| Classic FUO | Fever at least 38.3°C on at least two occasions, at least 3 weeks of illness, no known immunocompromise, and unrevealing baseline evaluation. [12] | Repeat history and examination; complete targeted baseline testing and pursue diagnostic clues before empiric therapy. [10][12][24] |
| Febrile neutropenia | Fever threshold with ANC below 1,500 cells/µL; ANC below 500 cells/µL is severe neutropenia. [13] | Treat as an oncologic infectious emergency; do not wait for a prolonged FUO workup. [13] |
| Nosocomial FUO | Fever arising in the hospital context, where underlying susceptibility and complications of hospitalization drive the differential. [5] | Review lines, procedures, medication exposures, and hospital-acquired complications. [5] |
| HIV-associated FUO | Fever in a person living with HIV, particularly if hospitalized. [5][21] | Evaluate infectious causes promptly; bacterial infections were the leading identified cause in one systematic review. [21] |

## Build the initial evaluation around potential diagnostic clues

The highest-yield next test is the one linked to a reproducible abnormality, exposure, or localizing finding.

Repeat a complete history and physical examination rather than treating the first assessment as definitive. Potential diagnostic clues include localizing symptoms, physical findings, laboratory abnormalities, and imaging abnormalities that suggest a specific cause; these clues should determine targeted microbiology, cross-sectional imaging, endoscopy, echocardiography, or tissue sampling. [10][24] Common etiologic categories remain infection, malignancy, and noninfectious inflammatory disease, but the working diagnosis should be a specific disease hypothesis rather than a broad category. [5][18]

For classic FUO, document the baseline laboratory and microbiologic evaluation before escalating: ESR, CRP, platelet count, leukocyte count with differential, hemoglobin, electrolytes, creatinine, total protein, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatine kinase, ferritin, antinuclear antibodies, rheumatoid factor, protein electrophoresis, urinalysis, blood cultures, urine culture, and chest radiography. [12] This panel is not a substitute for localization; interpret abnormalities as branching points for focused imaging or biopsy. [12][24]

Use inflammatory markers as activity signals rather than etiologic diagnoses. In one PET/CT FUO cohort, ESR above 20 mm/h, CRP above 0.8 mg/dL, and procalcitonin above 0.5 ng/mL were considered abnormal. [8] FDG-PET/CT evidence is insufficient for FUO with normal CRP and ESR, so a normal inflammatory-marker profile should prompt reassessment of the fever pattern, medications, and noninflammatory explanations before proceeding to advanced metabolic imaging. [11]

Direct targeted testing by pattern. New murmur, embolic phenomena, or persistent bacteremia should raise concern for endocarditis and support echocardiographic evaluation; echocardiography is also incorporated into many pre-PET FUO evaluations. [8][17] Pulmonary lesions require a focused infection-versus-malignancy assessment because lymphoma is reported as the most common malignant cause of FUO and may present with pulmonary lesions. [19] Myalgia with fever should retain adult-onset Still disease in the differential, particularly when the clinical syndrome supports it. [20]
- Obtain blood and urine cultures and chest radiography as part of baseline FUO evaluation. [12]
- Use ANA, rheumatoid factor, ferritin, CBC with differential, liver biochemistries, LDH, CK, and protein electrophoresis to identify inflammatory, hematologic, hepatic, or systemic diagnostic branches. [12]
- Treat a palpable or radiographically abnormal lymph node as a tissue target; lymph-node biopsy may establish malignancy, infection, or inflammatory disease. [10]
- Consider temporal-artery biopsy in a patient older than 60 years with substantially elevated ESR and symptoms suggestive of giant cell arteritis. [10]

### Etiologic branches that should change the next procedure

When examination or imaging identifies lymphadenopathy, prioritize excisional or otherwise adequate lymph-node sampling over nonspecific serologies when feasible; lymph-node biopsy is specifically recommended in FUO with lymphadenopathy. [10] When cytopenias, abnormal protein studies, organomegaly, or hematologic malignancy are suspected, bone-marrow biopsy is a recognized invasive FUO investigation. [8][10]

When the phenotype suggests large-vessel or cranial vasculitis, pursue anatomic or metabolic vascular evaluation and temporal-artery biopsy when the clinical threshold is met. Temporal-artery biopsy is most relevant in patients older than 60 years with markedly elevated ESR and compatible giant cell arteritis features. [10] Do not use isolated inflammatory-marker elevation as a reason for blind corticosteroid treatment. [5][6]

*Findings that should move evaluation from broad testing to a directed diagnostic action. [8][10][17][19][20]*

| Diagnostic clue | Leading branch | Directed next action |
| --- | --- | --- |
| Palpable or imaging-detected lymphadenopathy | Lymphoma, infection, inflammatory disease. [10][19] | Obtain lymph-node biopsy; select the most accessible clinically abnormal node. [10] |
| Cytopenias, suspected hematologic malignancy, or unexplained systemic findings | Marrow disorder, malignancy, disseminated infection. [8][10] | Consider bone-marrow biopsy when the clinical and laboratory pattern supports histopathologic evaluation. [8][10] |
| Age older than 60 years, high ESR, and symptoms compatible with giant cell arteritis | Giant cell arteritis. [10] | Consider temporal-artery biopsy. [10] |
| Persistent bacteremia, embolic pattern, or endocarditis clues | Infective endocarditis or metastatic infection. [17] | Perform echocardiographic evaluation and search for embolic or metastatic foci. [8][11][17] |
| Fever with myalgia and compatible systemic inflammatory phenotype | Adult-onset Still disease. [20] | Exclude competing infectious and malignant causes while applying syndrome-specific clinical assessment. [20] |

## Use FDG-PET/CT to localize a biopsy or treatment target

FDG-PET/CT is most useful after standard evaluation fails to identify a diagnosis and inflammatory activity remains present.

Order FDG-PET/CT for FUO or inflammation of unknown origin when standard workup has not established a diagnosis. [11] The test can identify infection, inflammation, and malignancy because FDG accumulates in activated inflammatory cells and in neoplastic cells with increased glycolysis. [24] Its principal clinical value is not merely an abnormal scan: use focal uptake to choose targeted imaging, biopsy, or disease-specific treatment. [11][24]

Before PET/CT, ensure that routine clinical, hematologic, biochemical, serologic, culture, and chest-radiographic evaluation has been completed and that conventional imaging or echocardiography has addressed relevant clues. [8][12] In one FUO cohort, CT, MRI, echocardiography, endoscopy, bone-marrow biopsy, temporal-artery biopsy, and organ or lymph-node biopsy were frequently performed before or alongside PET/CT, illustrating that metabolic imaging complements rather than replaces directed anatomic evaluation. [8]

If glucocorticoids are unavoidable, obtain FDG-PET/CT ideally within 3 days after oral glucocorticoid initiation. [11] When PET/CT identifies a lesion after a nondiagnostic CT-guided biopsy, use PET guidance to target the metabolically active portion of the lesion rather than repeating unguided sampling. [9] A negative FDG-PET/CT may support watchful waiting because it has been associated with favorable prognosis and spontaneous fever remission, but only after immediate threats and high-risk host states have been excluded. [11]
- Do not rely on FDG-PET/CT as a routine answer for FUO with normal CRP and ESR; evidence for that indication is insufficient. [11]
- Consider myocardial suppression preparation when a cardiac etiology is suspected on PET/CT. [11]
- Use PET-positive nodes, vessels, marrow, viscera, bone, or soft-tissue lesions to select the safest high-yield biopsy target. [9][11][24]

*FDG-PET/CT result-to-action framework. [9][11][24]*

| Result | Interpretation | Next action |
| --- | --- | --- |
| Focal metabolically active lesion | Potential infectious, inflammatory, or neoplastic focus. [24] | Obtain targeted tissue or focused confirmatory testing when feasible. [11][24] |
| Metabolically active region after nondiagnostic CT-guided biopsy | Prior sampling may have missed viable diagnostic tissue. [9] | Use PET-guided biopsy of the metabolically active component. [9] |
| Vascular uptake with compatible syndrome | Possible active vasculitic process. [9][24] | Correlate with inflammatory markers and pursue vasculitis-directed confirmatory evaluation, including temporal-artery biopsy when indicated. [10][24] |
| Negative scan after adequate standard workup | May predict favorable course with spontaneous fever remission. [11] | Consider observation with reassessment rather than empiric multidrug therapy in a stable, nonimmunocompromised patient. [5][11] |

## Avoid diagnostic-obscuring therapy unless the host or syndrome requires immediate treatment

Classic FUO and febrile neutropenia have opposite default treatment strategies.

In stable classic FUO, avoid empiric antituberculous drugs, broad antibacterial therapy, and glucocorticoids unless a specific clinical indication outweighs the loss of diagnostic clarity. Empiric therapy can obscure the underlying diagnosis and delay correct treatment, while prolonged undiagnosed FUO often has a favorable prognosis. [5] This restraint does not apply to febrile neutropenia, in which immediate empiric antimicrobial therapy is central to management. [13]

For low-risk febrile neutropenia managed as an outpatient, the cited oral regimen is ciprofloxacin 500 to 750 mg every 12 hours plus amoxicillin/clavulanate 500 mg every 8 hours; clindamycin is listed as an alternative for penicillin allergy. [13] Admit if fever persists 48 to 72 hours. [13] In high-risk patients with persistent fever after 4 to 7 days of broad-spectrum antibacterial therapy and suspected fungal infection, add empiric antifungal coverage. [13]

Avoid using a rapid fall in CRP after glucocorticoids as confirmation of noninfectious inflammatory disease. In an elderly patient with inflammation of unknown origin, empiric prednisolone 30 mg/day normalized CRP but was associated with delayed malignancy diagnosis and severe glucocorticoid-related complications, including compression fracture and venous thromboembolism. [6] Before initiating glucocorticoids for a presumed polymyalgia rheumatica-like syndrome or other inflammatory diagnosis, actively exclude malignancy and infection when the presentation is atypical or lacks confirmatory clues. [6]

For patients without a diagnosis after targeted evaluation, establish a reassessment plan rather than repeating the same broad tests. At each recurrence or follow-up visit, repeat focused history and examination, compare CBC, differential, liver tests, creatinine, ESR, and CRP with prior values, and re-open tissue diagnosis if new lymphadenopathy, cytopenias, vascular symptoms, focal imaging abnormalities, or organ-specific signs emerge. The negative-PET/CT watchful-waiting approach is appropriate only if the patient remains clinically stable and the initial evaluation has excluded high-risk infectious and malignant signals. [10][11][24]
- Classic FUO: withhold empiric antimicrobials and glucocorticoids when clinically safe; prioritize a diagnosis-directed test or biopsy. [5]
- Febrile neutropenia: treat promptly; do not defer therapy pending a prolonged FUO workup. [13]
- Persistent fever after 48 to 72 hours during cited low-risk outpatient neutropenia management requires admission. [13]
- Persistent fever after 4 to 7 days of broad-spectrum antibacterials in high-risk neutropenia with suspected fungal infection supports empiric antifungal coverage. [13]

*Default management differs by clinical context. [5][6][13]*

| Clinical context | Default treatment posture | Escalation trigger |
| --- | --- | --- |
| Stable classic FUO | Withhold empiric antibacterial, antituberculous, and glucocorticoid therapy when possible to preserve diagnostic yield. [5] | New instability, a defined focal syndrome, or a microbiologic, imaging, or pathology diagnosis. |
| Low-risk febrile neutropenia | Ciprofloxacin 500-750 mg orally every 12 hours plus amoxicillin/clavulanate 500 mg orally every 8 hours; use clindamycin for penicillin allergy. [13] | Persistent fever at 48-72 hours requires admission. [13] |
| High-risk neutropenia with persistent fever | Continue broad-spectrum antibacterial management; evaluate for fungal infection. [13] | After 4-7 days with suspected fungal infection, add empiric antifungal coverage. [13] |
| Uncertain inflammatory syndrome | Avoid diagnostic glucocorticoids before reasonable exclusion of infection and malignancy. [5][6] | If glucocorticoids are unavoidable and PET/CT is planned, perform PET/CT ideally within 3 days of starting oral therapy. [11] |

## Common questions

### When should an undiagnosed febrile patient receive empiric antibiotics rather than continued FUO testing?

Use immediate empiric antimicrobial management for febrile neutropenia rather than a prolonged classic FUO pathway. In stable, nonimmunocompromised classic FUO, avoid empiric antibacterial, antituberculous, and glucocorticoid therapy when possible because these interventions can obscure the diagnosis. [5][13]

## References
1. EQUAL Aspergillosis Score 2018: An ECMM score derived ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/myc.12820
2. Decreased febrile neutropenia during inpatient ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/cas.15490
3. Conference Report 33rd European Congress on Clinical ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/tid.14146
4. ABSTRACTS - 2022 - Pediatric Blood & Cancer - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/pbc.29735
5. Fever of Unknown Origin: An Evidence-Based Review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S000296291530834X
6. Risks of empiric glucocorticoid administration in... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2025/04180/risks_of_empiric_glucocorticoid_administration_in.34.aspx
7. Giant Ovarian Cystadenofibroma Mimicking Ascites in an Elderly Adult — agsjournals.onlinelibrary.wiley.com — https://agsjournals.onlinelibrary.wiley.com/doi/pdf/10.1111/jgs.12081
8. Diagnostic Value of 18F-FDG-PET/CT in Patients with FUO - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7408628
9. Abstracts — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10798254
10. Fever of Unknown Origin - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK532265
11. EANM/SNMMI guideline/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0 — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11732780
12. Optimal use of the FDG-PET/CT in the diagnostic process of fever of unknown origin (FUO): a comprehensive review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9616755
13. Febrile Neutropenia - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK541102
14. Pediatric Fever of Unknown Origin - AAP Publications — pedsinreview.aappublications.org — http://pedsinreview.aappublications.org/cgi/doi/10.1542/pir.36-9-380
15. Fungal Infections in Pediatric Patients With Hematologic ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1155/cjid/8766717
16. Fever of Unknown Origin From the Primary Care Perspective: A ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/carm/9086960
17. Fever of Unknown Origin - Lamphier - 1980 - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.1980.tb08150.x
18. Fever of unknown origin in adults: 40 years on - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2796.2003.01120.x
19. Etiological distribution and clinical features of fever of unknown ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/crj.13070
20. Acute Adult‐Onset Still Disease Presenting as Fever of Unknown ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1155/carm/6925896
21. Aetiology of fever of unknown origin in people living with HIV: A ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/hiv.70080?af=R
22. Nuclear Medicine Imaging of Fever of Unknown Origin - Diagnostic ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/9781118484388.ch16
23. Secondary syphilis presenting as fever of unknown origin - Wilding ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/ccr3.8583
24. State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8271312

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.